Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mike Wallace would not let verbiage like "I think probably" inspire such confidence, JL.
it's on my watch list. but it's more of a commodity play than a value play. the big run up they had was due to the copper/metals bubble this summer. kind of scary. i haven't had time to look at the chart/sentiment indicators as all my dumb money is tied up in GTCB. but it's an interesting beat up stock.
Honestly, what would you expect him to say even if he were years from closing a deal? Haven't you noticed the great talent for ambiguity and vagueness GTCB executives seem to share?
Fixed it for ya.
"For instance, following the LFB financing deal I unloaded most of my $1.25 shares at about $0.25. Then, when the stock dropped to below $0.14, I reloaded..."
Why do you think this, GS?
My off-the-cuff observation is that all of the progress made by the company has simply been "spent" in dilutions. The market cap hasn't fallen nearly as much as the share price, overtime.
Does anyone have access to a market cap chart?
I'm not sure what you are "talking about" but I am glad that you describe me as perfect. Don't you think that the increase in share price should be attributed primarily to intervening events between then and now? After all, their checking account balance was nearly zero, further financing was not assured and the FDA hadn't said any nice things about Atryn. Was 11 cents/share really that irrational given conditions of the company and the financial system?
BTW, you should note that my post didn't advocate selling at 11 cents, just that the present value of GTCB stock might have been eclipsed by a potential tax deduction.
Stocks and stock markets are not zero sum games. Your parroted premise does nothing to support your conclusion. FAIL.
How do you suppose GTCB will pay back LFB? Sell another 50 million shares? They'll have to raise $10 million for that on top of what they need to fund their quarterly burn. This is the essential problem with GTCB. They are a financial train wreck.
Hopefully they are not as dumb as I suspect they are and are setting up for a sell to one of the big pharma's.
You're overlooking half of the story again, V. They still have no meaningful revenue in sight, still need to raise operating capital and look to be majority owned by LFB in a few months. These are real risks to the stock price. Not sure why you're so offended that someone takes some profits. Seems rather prudent.
You're overlooking half of the story again, V. They still have no meaningful revenue in sight, still need to raise operating capital and look to be majority owned by LFB in a few months. These are real risks to the stock price. Not sure why you're so offended that someone takes some profits. Seems rather prudent.
Hopefully, but GTCB has never displayed much prescience regarding such things.
rough spots? please iron it out for us go seek.
what does "a smooth birth to a healthy People" mean?
is engrish your second ranguage?
Go Seek, come on, what does this even mean?
"CD20" cows in China
Article dated August 13th, 2008, do not remember seeing this previously...
Li Ning from China Agricultural University, Academician of the leading R & D team, and Beijing Ji Pu-Lin Biotechnology Co., Ltd. and the Beijing Branch of China Dwyane Wade biotechnology co-operation of limited liability company, said recently in Beijing in transgenic animal testing base, a smooth birth to a healthy People "CD20 antibody genes" of transgenic cows, the first transgenic cows born weighing 38 kg, in good health.
Human CD20 monoclonal antibody therapy is malignant B-lymphocytes, such as the effects of drugs. The current way through the mammalian cell culture production of CD20 antibody, the United States is the first FDA-approved anti-tumor monoclonal antibody drugs, the annual global sales of more than 3 billion U.S. dollars. However, such a person CD20 antibody drug production costs are high, high prices, a course of treatment (injection of four) to be 16,000 U.S. dollars, for the majority of patients are enormous burden.
Academician Li Ning R & D team is the project through transgenic technology, access to transgenic cows mammary gland bioreactor, the transgenic cows milk containing human CD20 monoclonal antibody, through the purification of monoclonal antibody cancer vaccine or treatment, and can be produced To reduce the cost of one-tenth of the original, is expected to open up a new way to produce monoclonal antibodies, so as to the world of B lymphocytes, such as cancer patients bring the gospel.
Animal mammary gland bioreactor pharmaceutical genetic engineering is the latest stage, is a new mode of production, more than ever pharmaceutical technology has unparalleled advantages: First, the production of pharmaceutical proteins varieties, high yield, a stable The natural biological activity and the other is a short production cycle, low-cost third is environmental safety, equipment simple, low energy consumption, no pollution. Based on animal mammary gland bioreactor huge business outlook, governments and enterprises have increased the animal mammary gland bioreactor research and development investment, in a bid to the animal mammary gland bioreactor industry a place in international competition.
The transgenic cows successful, indicates that China's animal bioreactor research and development has entered a higher stage of development, the use of transgenic animals producing antibody drugs in Europe and the United States and the developed countries simultaneously, antibody drugs for low-cost, large-scale production Laid a solid foundation for the future will greatly enhance our country's medical standards and people's health.
Considering that the threshold for approval was around 51 million votes, it looks like proposals 1 & 2 barely passed.
Essentially, all votes started out as "No" votes so the only people (shares) with any real incentive to vote are the ones in support of the proposals. Management shouldn't consider the margins a ringing endorsement.
Also, consider that LFB and management voted their shares (well over 20 million) for the deal and you see support from less than a third of the remaining shares.
But you are right that it doesn't matter now.
management throws up hands, blames stupid Wall Street, returns to previously scheduled cocktail party
"Regrettably, Wall Street has chosen to ignore the value of the work we are doing..."
What a bunch of claptrap. Aren't you asking shareholders to perform one of the primary jobs of the company?!?!?! Face it, the real villians are the shareholders who have blindly followed (and voted for) Cox and the Board of Directors. Share price of 18 cents is ample proof of that.
If "The Problem" is out of management's control, then mistakes regarding stock buykbacks, loss of product, and poor negotiating technique (et al) become non-trivial.
They've run this company like a grad student with grant money.
By a wide margin, I-Hubbers have voted Geoffrey Cox:
Worst pharma/biotech ceo of the year; and
Worst pharma/biotech ceo of ALL TIME.
http://tinyurl.com/5o5vom
6 year old news. point?
Cash doesn't cover accounts payable. wow.
As far as I can tell, Leo's total sales of Atryn is $0.00. Is there any contrary evidence?
i've always thought that atryn was mispriced. part of the goat's schtick is being able to produce cheaply. so why not sell the first one cheaply instead of at a premium price? and then rebrand at a higher price for other indications. or have a successful low margin product and let the higher ones follow. cox f'd it up when he jumped in bed with leo and assumed it was salad days.
gs:
your highlighting pen should have bolded the most telling and reocurring words of the whole gtcb story:
slower than planned
OB, don't look now but I think you have made your decision. I guess my decision is contrary. That's fine. We're adults.
Ya know, all we can do is try to be intellectually honest and distill an idea from the facts presented. While there are lots of great opinions floating around this board, most aren't distilled from fact. IMHO, ideation and denial are an ongoing motif.
13 cents/share? I think it's foolhardy to vote for anything proposed by the people who got it there. Their proposal tacitly says "we will do anything for more money as long as it maintains the status quo". And what about this deal, isn't it really, bottom line, just a convoluted sale? Why else are we voting on it. There is always an alternative.
I suspect we've seen our last annual shareholder meeting, BTW. The leaders of failed companies can rarely stand such a spot light.
I have no doubt that the LFB reorganization is the best deal that allowed management to maintain the status quo. I'm going to vote "No" to help upset that apple cart. The company should be sold to the highest bidder not the highest bidder that keeps Geoffrey Cox in the pink.
Sadly, this stock is worth much more, to most of us, as a tax loss than as an investment at this point.
Thank you for pointing out my laziness. Still, it seems a little beyond the pale that the vp of whatever won't provide BOD contact info to a shareholder.
i'll give you a hug if you can name a board member and provide contact info
tom newberry is jealous about such info.
I don't see how this is essential to the survival of the company. I encourage all fellow shareholders to vote against #2.
2. To approve an amendment to GTC’s 2002 Equity Incentive Plan (the “2002 Plan”) to increase by 2,000,000 shares the number of shares of common stock available for issuance under the 2002 Plan and amend the annual adjustment provision under the 2002 Plan...